Sakar Healthcare earnings calls.
Other · 2 quarters tracked · source-linked performance, management guidance and promise context.
Latest revenue
₹71.097 Cr
verified financial record
Quarters tracked
2
source records in the directory
Delivery assessment
0
Across 2 tracked commitments: 0 delivered, 2 missed.
Call date
2026-04-??
latest available source date
Signal trajectory
2 actual quartersCurrent read
0/100
Across 2 tracked commitments: 0 delivered, 2 missed.
Latest source read
What changed this quarter?
Sakar Healthcare delivered a strong Q4 FY26 with revenue of ₹71.1 crore (+42% YoY), EBITDA of ₹26.2 crore (37% margin), and PAT of ₹11.0 crore (+91% YoY). The oncology division contributed 38% of full-year revenue, up from 21% last year, driven by domestic growth and initial export traction. Management guided for ~40% revenue growth in FY27, targeting oncology revenue to double to ~₹200 crore, supported by 60+ signed contracts, 125 dossier filings, and tech transfers with Accord, Torrent, and others. The oncology facility (capacity utilization <30%) can scale to ₹800-1,000 crore with minimal capex. Risks include lumpy export order patterns and potential delays in regulatory approvals for the remaining seven Accord products.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Positive
Revenue
₹71.097 Cr
Source date
2026-04-??
Across the record
Quarter history.
History modules